SOURCE: Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

March 12, 2015 16:30 ET

Esperion Therapeutics to Present at Bank of America Merrill Lynch Smid Cap and BioCentury Future Leaders in the Biotech Industry Conferences

ANN ARBOR, MI--(Marketwired - March 12, 2015) - Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced president and chief executive officer, Tim M. Mayleben, will present an overview of the Company at the following conferences:

  • Bank of America Merrill Lynch Smid Cap Conference 2015 in Boston, MA on Wednesday, March 18, 2015 at 11:45 a.m. Eastern Time.
  • 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York City on Friday, March 20, 2015 at 11:00 a.m. Eastern Time.

A live, listen-only webcast of the Bank of America Merrill Lynch Smid Cap Conference presentation can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the presentation will be available approximately one hour after completion and will be archived on the Company's website for 90 days following the event.

Esperion's Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two preclinical product candidates.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with therapies currently available for lowering LDL-cholesterol. ETC-1002 is being developed for patients with hypercholesterolemia, including those with a history of statin intolerance. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.

Contact Information